Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11488710 | 0.88 | SETD7 (0.79) | SETD7OPRD1LMNACHRM2CYP2D6 | |
| SCHEMBL14262785 | 0.82 | SETD7 (0.67) | SETD7OPRD1LMNACHRM2CYP2D6 | |
| SCHEMBL4926062 | 0.81 | OPRD1 (1.00) | SETD7OPRD1OPRK1OPRM1 | |
| SCHEMBL13437754 | 0.81 | SETD7 (0.66) | SETD7OPRD1OPRM1DRD2DRD1 | |
| SCHEMBL14262771 | 0.80 | SETD7 (0.67) | SETD7OPRD1MEN1KMT2AMAOA | |
| SCHEMBL14198384 | 0.80 | SETD7 (0.66) | SETD7OPRD1LMNACHRM2CYP2D6 | |
| SCHEMBL1774131 | 0.79 | SETD7 (0.64) | SETD7OPRD1LMNACHRM2CYP2D6 | |
| SCHEMBL14198385 | 0.79 | SETD7 (0.65) | SETD7OPRD1LMNACHRM2CYP2D6 | |
| SCHEMBL14262776 | 0.78 | SETD7 (0.61) | SETD7OPRD1LMNACHRM2CYP2D6 | |
| SCHEMBL11391911 | 0.78 | SETD7 (0.64) | SETD7OPRD1LMNACHRM2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493420-B2 | Quinoline derivatives and uses thereof | PORTLAND STATE UNIVERSITY (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493420-B2 | Quinoline derivatives and uses thereof | PORTLAND STATE UNIVERSITY (US) | 2016-11-15 | — | — | US | disclosed |
| US-20130310348-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | STATE UNIVERSITY (US) | 2013-11-21 | — | — | US | disclosed |
| US-8524739-B2 | Quinoline derivatives and uses thereof | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524739-B2 | Quinoline derivatives and uses thereof | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110257160-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | Board of Higher Education on behalf of Portland State University | 2011-10-20 | — | — | US | disclosed |
| US-20110257160-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | Board of Higher Education on behalf of Portland State University | 2011-10-20 | — | — | US | disclosed |
| US-7968539-B2 | reversed chloroquines; to treat chloroquine resistant/sensitive malaria parasites; N'-(7-Chloro-quinolin-4-yl)-N-[3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-N-methyl-propane-1,3-diamine | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968539-B2 | reversed chloroquines; to treat chloroquine resistant/sensitive malaria parasites; N'-(7-Chloro-quinolin-4-yl)-N-[3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-N-methyl-propane-1,3-diamine | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2011-06-28 | — | — | US | disclosed |
| EP-1742707-A4 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1742707-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | Hypnion, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005103041-A9 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005103041-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050080265-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050009730-A1 | Treatment of cns disorders using cns target modulators | HYPNION, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2003032912-A9 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-1443929-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | Hypnion, Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040142972-A1 | CNS target modulators | HYPNION, INC. | 2004-07-22 | — | — | US | disclosed |
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003032912-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009730-A1 | Treatment of cns disorders using cns target modulators | HCRTR2, CNR2, CNR1 | SETD7 1332/4885OPRD1 645/4885LMNA 3626/4885 |
| US-20130310348-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | RECQL, QARS1, QTRT1 | SETD7 2366/4885OPRD1 3693/4885LMNA 3368/4885 |
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HCRTR2, CNR2, CNR1 | SETD7 1332/4885OPRD1 645/4885LMNA 3626/4885 |
| US-20110257160-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | RECQL, QARS1, QTRT1 | SETD7 2366/4885OPRD1 3693/4885LMNA 3368/4885 |
| US-20050080265-A1 | Treatment of CNS disorders using CNS target modulators | HCRTR2, HRH3, HCRTR1 | SETD7 838/4885OPRD1 554/4885LMNA 4049/4885 |
| US-20040142972-A1 | CNS target modulators | HCRTR2, CNR2, CNR1 | SETD7 1434/4885OPRD1 399/4885LMNA 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.